Semaglutide for children younger than 12 now has its first late-stage trial result. It does not have a new label for that age group. For a parent, that is the most important distinction: STEP Young is meaningful research, not permission to treat a child without a pediatric specialist.
As of September 9, 2026, the day this article was written, Novo Nordisk had reported its STEP Young results on September 7, and a separate Pediatrics study published September 4 showed that prescribing of GLP-1 medicines in younger children had already risen sharply. The trial tested what happened to body mass index (BMI), a height-adjusted measure of body size. The records study counted prescriptions. Neither answers every long-term question a family would reasonably ask.
What semaglutide for children showed in STEP Young
STEP Young assigned children to semaglutide or placebo by chance and kept families and study staff from knowing which one they received during treatment. It enrolled 165 children ages 6 to under 12 with obesity. More than 85% began with severe obesity.
Both groups also received support for a reduced-calorie diet and increased physical activity. At week 68, 40.4% of children assigned semaglutide were below the obesity threshold on age- and sex-specific growth charts, compared with 0% assigned placebo. That figure is Novo's estimate of the effect if every child had stayed on treatment. The main endpoint—the result researchers selected in advance—was the percentage change in BMI from the start of the trial. Novo said that result favored semaglutide but did not publish the size of the average change in its announcement.
That last point matters. These are company-reported topline results, a short first release rather than a peer-reviewed paper with full tables. Novo said detailed findings are planned for ObesityWeek in November 2026.
What the result does not tell us
Sixty-eight weeks is long enough to measure a change in BMI. It is not long enough to settle how treatment affects a young child across years of growth, what happens after medication stops, or which children are most likely to benefit or have trouble with it.
Novo reported no new safety concerns and no signal involving growth or pubertal development. That is reassuring. It is not the same as having the full side-effect tables or years of follow-up. The announcement also says some other measurements run to week 104, so the evidence will keep developing.
The trial used once-weekly injections at maximum doses chosen by starting weight. Those are study facts, not a dosing plan for a child. A pediatric prescriber would make any dosing decision.
Prescribing was already rising before the result
The new Pediatrics research brief looked at electronic health records for 3,520,531 children ages 8 to 11 who had obesity without diabetes. Across the 2019-to-June-2026 study period, 0.6% received a prescription for one of three GLP-1 receptor agonists: Saxenda, Wegovy, or Zepbound. A GLP-1 receptor agonist is a medicine that copies part of a natural fullness-and-blood-sugar signal.
The authors reported that the share prescribed in a given year rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase. It was higher among 11-year-olds than 8-year-olds, among girls, among children with obesity-related health conditions, and in areas with less social vulnerability, a measure of community-level social and economic barriers.
This was a records study, not a treatment trial. It cannot show why each prescription was written, whether the medicine was taken, or what happened afterward. Because it grouped liraglutide, semaglutide, and tirzepatide products together, it also cannot be read as a semaglutide outcome study.
What the current Wegovy label allows
The new STEP Young result is not FDA approval for ages 6 to 11. The June 2026 Wegovy prescribing information says the injection is indicated for weight management in children ages 12 and older with obesity. It says safety and effectiveness for that purpose have not been established below age 12.
That age-12 threshold rests in part on STEP TEENS, a 2022 trial of 201 adolescents. At 68 weeks, mean BMI changed by -16.1% with semaglutide and 0.6% with placebo; both groups received diet and physical activity support. Stomach and bowel events occurred in 62% and 42%, respectively, and gallstones were reported in 4% of the semaglutide group and none of the placebo group (Weghuber et al., New England Journal of Medicine, 2022). Those numbers describe adolescents and cannot simply be carried down to a 7-year-old.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a licensed pharmacy prepares a medication for an individual prescription. Adults can read more about what compounded semaglutide means. A licensed provider may still prescribe a compounded formulation to an adult when clinically and legally appropriate; that decision is between the patient and the doctor.
The questions a parent still needs answered
For a child, the useful conversation is larger than a number on a scale. A pediatrician may consider the severity and history of obesity, blood pressure and laboratory findings, other medicines, eating patterns, mental health, family circumstances, and whether intensive lifestyle support is available.
The follow-up plan matters too. Families deserve a plain explanation of how growth and puberty will be watched, which stomach symptoms are expected, what would prompt a call, and how nutrition will be protected when appetite falls. The known effects in older patients are covered in our semaglutide side-effects guide, but a younger child should not be assumed to have the same experience.
This is also a moment for care without blame. Obesity is a medical condition, and the children in STEP Young overwhelmingly had severe disease. A thoughtful appointment should make room for health, development, and quality of life without turning a child's body into a moral judgment.
Where Promise's boundary sits
Promise's semaglutide intake is only for adults age 18 and older. A licensed provider reviews every request, and not everyone qualifies. A child's care belongs with a pediatrician or pediatric obesity specialist who can coordinate growth, nutrition, mental health, and family support.
What to watch next
The next useful evidence is the full STEP Young dataset: the actual average BMI change, side effects by group, how many children stopped treatment, growth and puberty measurements, and longer follow-up. FDA review would be a separate step after that. Until a label changes, the label in force is the answer.
The new result moves the science forward. It does not move the age line on its own.